MÉDICA SUR, S.A.B. DE C.V. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38 MXN | -2.09% |
|
-3.31% | -6.47% |
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -6.47% | 247M | - | C+ | |
| +16.49% | 83.4B | C+ | ||
| -29.52% | 72.11B | B- | ||
| 0.00% | 27.04B | C+ | ||
| -13.29% | 16.96B | B | ||
| +1.03% | 16.86B | A- | ||
| +1.57% | 15.76B | A- | ||
| +71.63% | 13.33B | C- | ||
| +1.53% | 12.76B | B- | ||
| +70.68% | 12.74B | C+ |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MEDICA B Stock
- Ratings Médica Sur, S.A.B. de C.V.
